Loading…
Loading…
EQUITY / NASDAQ · XNMS
ReShape Lifesciences, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.91 USD · 0%
Observed: Oct 2, 2026, 8:00 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/02/2026 · 1.91 USD · Volume 20,232
681 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Revenue | 26,955 USD | 49,954 USD | -46.04% |
| Operating profit | -862,566 USD | -324,189 USD | — |
| Net income | -685,556 USD | -308,760 USD | — |
| Cash and cash equivalents | 7,887,510 USD | — | — |
| Total liabilities | 1,864,656 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 7,887,510 USD | — | — | 4,982,333 USD | 4,982,333 USD | 5,707,012 USD | — | — |
| Gross profitIncome statement | 11,658 USD | 28,303 USD | — | — | 218,771 USD | 18,050 USD | 196,705 USD | 24,235 USD |
| Net incomeIncome statement | -685,556 USD | -1,648,466 USD | -985,521 USD | — | -10,262,007 USD | -8,433,811 USD | -9,036,544 USD | -308,760 USD |
| Operating profitIncome statement | -862,566 USD | -1,992,506 USD | — | — | -10,452,570 USD | -8,574,310 USD | -9,097,496 USD | -324,189 USD |
| RevenueIncome statement | 26,955 USD | 58,546 USD | — | — | 319,714 USD | 34,627 USD | 283,163 USD | 49,954 USD |
| Total assetsBalance sheet | 9,176,362 USD | — | — | 6,497,177 USD | 6,497,177 USD | 7,045,396 USD | — | — |
| Total equityBalance sheet | 7,311,706 USD | — | 8,041,321 USD | 3,762,017 USD | 3,762,017 USD | 2,529,713 USD | — | -4,993,754 USD |
| Total liabilitiesBalance sheet | 1,864,656 USD | — | — | 2,735,160 USD | 2,735,160 USD | 3,126,936 USD | — | — |
| Financing cash flowCash flow statement | — | 5,285,868 USD | — | — | 8,654,976 USD | — | 7,890,956 USD | — |
| Operating cash flowCash flow statement | — | -2,339,676 USD | — | — | -3,748,853 USD | — | -2,270,655 USD | — |
| Report source | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 03/18/2026 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 08/12/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.